Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New anesthesia drug could make surgery safer for seniors

NCT ID NCT06690424

Symptom relief Sponsor: Affiliated Hospital of Nantong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares remimazolam, a newer sedative, to the standard drug propofol for anesthesia in 92 elderly patients (ages 60-75) undergoing thyroid surgery. The goal is to see if remimazolam provides smoother induction, stable vital signs, and faster recovery with fewer complications like confusion or irregular heartbeat. Results could lead to a safer anesthesia choice for older adults.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Remimazolam
What this could lead to
If successful, remimazolam could offer a safer anesthesia option for elderly patients, with fewer side effects like low blood pressure or confusion after surgery.
What could go wrong
This is a small, single-center trial with only 92 participants, so results may not apply to all elderly patients. Remimazolam may not prove better than propofol in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

92 people

The number who actually took part.

Started

Jun 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients undergoing surgery for clinically diagnosed thyroid tumors 2. Patients with general anesthesia 3. Patients requiring endotracheal intubation 4. American Society of Anesthesia gradeⅡ to grade Ⅲ 5. age 60-75 years old 6. body mass index was between 18 and 28 7. Patients or their family was clear about the study process and volunteered to participate. Exclusion Criteria: 1. Patients with known allergy to remimazolam or with previous history of severe allergy and family history 2. Patients with long-term use of narcotic analgesics, sedatives, or non- steroidal anti-inflammatory drugs 3. Patients with drug taking, opioid dependence or tolerance 4. Patients with combined brain injury or intracranial hypertension 5. Patients with severe abnormal function of the heart, lung, liver, kidney and other major organs 6. Patients with bradycardia, with a heart rate lower than 55 beats / minute or a high atrioventricular block 7. Patients with a previous history of allergic disease 8. Patients with a previous history of mental illness 9. Patients with a foreseeable difficult airway 10. The investigator does not consider it appropriate to attend this clinical investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Efficacy and safety are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

thyroid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Efficacy and safety

Contacts and locations

Locations

  • Affiliated Hospital of Affiliated Hospital

    Nantong, Jiangsu, 226001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.